MvDN30

MvDN30 is a **chimeric monovalent Fab fragment of the DN30 monoclonal antibody** engineered for cancer therapy. Its mechanism of action is unique: MvDN30 binds to the Met receptor and induces its shedding from the cell surface by activating membrane proteases, leading to the release of the entire N-terminal Met domain. This reduces surface Met receptor density and the released domain acts as a decoy, inhibiting receptor dimerization and downstream signaling. MvDN30 thus functions as a full Met antagonist, impairing Met phosphorylation and the associated cellular growth responses[1]. PEGylation and protein engineering strategies have been employed to enhance its half-life and pharmacokinetics. In preclinical cancer models, MvDN30 and its engineered derivatives inhibit Met-driven tumor growth[1]. The primary indication is for Met-addicted cancers.

Brand names

MvDN30MvDN-30MvDN 30

Other names

DN30 FabDN-30 FabDN 30 Fabchimeric monovalent Fab fragment of DN30 monoclonal antibody